| 000 | 01807 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513163104.0 | ||
| 264 | 0 | _c19990330 | |
| 008 | 199903s 0 0 eng d | ||
| 022 | _a0022-1899 | ||
| 024 | 7 |
_a10.1086/314639 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKaravellas, M P | |
| 245 | 0 | 0 |
_aIncidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. _h[electronic resource] |
| 260 |
_bThe Journal of infectious diseases _cMar 1999 |
||
| 300 |
_a697-700 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xcomplications |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCalifornia _xepidemiology |
| 650 | 0 | 4 | _aCidofovir |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCytomegalovirus Retinitis _xcomplications |
| 650 | 0 | 4 |
_aCytosine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aEye Diseases _xepidemiology |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aInflammation |
| 650 | 0 | 4 | _aOrganophosphonates |
| 650 | 0 | 4 |
_aOrganophosphorus Compounds _xtherapeutic use |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSyndrome |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aVisual Acuity |
| 650 | 0 | 4 |
_aVitreous Body _ximmunology |
| 700 | 1 | _aPlummer, D J | |
| 700 | 1 | _aMacdonald, J C | |
| 700 | 1 | _aTorriani, F J | |
| 700 | 1 | _aShufelt, C L | |
| 700 | 1 | _aAzen, S P | |
| 700 | 1 | _aFreeman, W R | |
| 773 | 0 |
_tThe Journal of infectious diseases _gvol. 179 _gno. 3 _gp. 697-700 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1086/314639 _zAvailable from publisher's website |
| 999 |
_c9913944 _d9913944 |
||